Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants
Bin Tu, Huiyuan Wang, Xinran An, Jingkun Qu, Qianqian Li, Yanrong Gao, Mingjie Shi, Hong Qiu, Yongzhuo Huang
Abstract
The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery.Image 1.
Topics & Concepts
HeparinCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PolysaccharideMedicinePharmacologyChemistryInternal medicineBiochemistryInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesDermatological and COVID-19 studiesThermal Regulation in Medicine